Sara Thønnings

Sara Thønnings

Auto-generated profile, based on publicly available information

Sara Thønnings

Department of Clinical Microbiology, Copenhagen University Hospital, Hvidovre, Denmark

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2016 in Clinical Microbiology and Infection
Verified
Journal Article
Closed access
STS. Thønnings
S. Thønnings
JKJ.D. Knudsen
J.D. Knudsen
HSH.C. Schønheyder
H.C. Schønheyder
MSM. Søgaard
M. Søgaard
MAM. Arpi
M. Arpi
JSJ. Smit
J. Smit

16 May 2019 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Closed access
JBJonas Boel
Jonas Boel
FJFilip Jansåker
Filip Jansåker
FHFrederik Hertz
Frederik Hertz
KHKatrine Hartung Hansen
Katrine Hartung Hansen
STSara Thønnings
Sara Thønnings
JKJenny Dahl Knudsen
Jenny Dahl Knudsen
Objectives: To evaluate the importance of treatment duration for therapeutic efficacy of pivmecillinam for community-acquired urinary tract infections (UTIs) caused by Escherichia coli. Methods: A retrospective cohort study was conducted between 1 January 2010 and 30 September 2016 in adults with community-acquired E. coli bacteriuria, treated empirically with pivmecillinam. Regimens of 3, 5 and 7 days were compared using clinical treatment failure (i.e. redemption of a new antibiotic or hospitalization due to UTI) within 14 and 30 days as outcome. HR and risk difference with 95% CI were estimated for treatment failure. Results were stratified by age (18–50, 51–70, >70 years) and sex. Results: Of the 21864 cases of E. coli UTI that were analysed, 2524 (11.5%) were in men. In 954 cases (4.4%) E. coli produced ESBL and 125 (13.1%) of the cases were in men. The 3 day regimen increased the risk of treatment failure for all groups. The risk differences between the 3 and 5 day regimens were 10% for men. Comparing the 7 day and 5 day regimens, only women aged >50 years demonstrated an increased risk of treatment failure within 14 days with the 5 day regimen, but not within 30 days. Conclusions: With the current data, where data on clinical classification of the E. coli UTI were missing, a 5 day treatment with pivmecillinam at 400 mg three times daily seems to be the rational recommendation for lower UTI in men, pregnant women and women >50 years old. A 3 day regimen seems sufficient for non-pregnant women <50 years old.

1 July 2019 in eClinicalMedicine
Verified
Journal Article
Open access
FJFilip Jansåker
Filip Jansåker
STSara Thønnings
Sara Thønnings
FHFrederik Hertz
Frederik Hertz
TKThomas Kallemose
Thomas Kallemose
JVJan Værnet
Jan Værnet
JKJenny Dahl Knudsen
Jenny Dahl Knudsen
To investigate if a 5-day course pivmecillinam (amdinocillin pivoxil) 400 mg three times daily is superior to a 3-day course in women with uncomplicated urinary tract infection (UTI). A randomised, double-blind, placebo-controlled trial conducted at nine primary care centres in Denmark. 368 women (18-70 years) with symptoms compatible with UTI were randomised to blinded therapy of 5 days [5d] or 3 days followed by 2 days of placebo [3d] from May 2015 to November 2017. Clinical data were assessed using a validated questionnaire at inclusion (day-0), daily the following 7 days and once again within the 2nd to 6th week after intervention. Bacteriological data were collected prior to intervention and twice between day 7 and 42. Main clinical endpoints were days to symptom resolution within 7 days after inclusion and proportions with clinical success at the end of intervention. Main bacteriological endpoint was proportion of participants with significant reduction of bacteriuria (≥ 102 CFU/mL) in 1st control urine sample. ClinicalTrialsRegister.eu: 2014-001321-32. 180 (5d) and 188 (3d) participants were included in the study (mean age: 35.4 [5d] and 34.9 [3d]). Of these, 125 (70% [5d]) and 122 (66% [3d]) had a positive baseline urine culture. Forty-four participants were lost to follow-up, leaving 161 [5d] and 163 [3d] participants for analysis, respectively. Mean time to symptom resolution was 2.91 (SD 1.46; [5d]) days and 2.94 (SD 1.42; [3d]) days (P = .894). Clinical success at the end of treatment occurred for 117 of 153 (76%) receiving the 5d-course and for 115 of 157 (73%) receiving the 3d course (difference 3.2% [95% CI -7.1% - 13.5%]; P = .601). Bacteriological success was seen in 92 of 104 (88%) participants given the 5d course and in 86 of 99 (87%) given the 3d course (difference 1.6% [95% CI -8.4%-11.6%]; P = .895). A 5-day course of pivmecillinam was not superior to a 3-day course in clinical or bacteriological outcomes for UTI. The Danish Regions [no. 14/217].

16 July 2023 in Preventive Medicine Reports
Verified
Journal Article
Open access
HSHenning Stenberg
Henning Stenberg
XLXinjun Li
Xinjun Li
WPWazah Pello-Esso
Wazah Pello-Esso
SLSara Larsson Lönn
Sara Larsson Lönn
STSara Thønnings
Sara Thønnings
FJFilip Jansåker
Filip Jansåker
• This study explores population-based risk factors for sepsis. • The study utilized nationwide registers and primary healthcare data. • High age and sociodemographic factors are associated with sepsis. • The effect of high age is more than twice as high in men than in women. • Somatic and mental disorders are also independently associated with sepsis.

1 March 2020 in Journal of Medical Microbiology
Verified
Journal Article
Open access
STSara Thønnings
Sara Thønnings
KJKlaus Skovbo Jensen
Klaus Skovbo Jensen
NNNinna B. Nielsen
Ninna B. Nielsen
MSMartin Skjønnemand
Martin Skjønnemand
DHDennis S. Hansen
Dennis S. Hansen
Niels Frimodt-MøllerNiels Frimodt-Møller
Niels Frimodt-Møller
Introduction. Cefuroxime is an important antibiotic to treat several serious infections. Rapid elimination through the kidneys and the variation in MICs of various susceptible pathogens such as Escherichia coli, Klebsiella pneumoniae, Staphylococcus aureus and Streptococcus pneumoniae give rise to dosing issues, especially in otherwise healthy patients. Aim. To investigate the probability of target attainment (PTA) for obtaining the optimal dosage regimens for cefuroxime in healthy young people. Methodology. Two weeks apart 750 and 1500 mg cefuroxime were administered as an intravenous bolus to 20 healthy volunteers (mean age: 27 years). Population modelling and simulation studies were done based on the obtained data for cefuroxime plasma concentration. Results. With a target value of time above MIC (T >MIC) greater than 50 % the simulations revealed that a PTA of >99 % is obtained for S. pneumoniae with a dosage regimen of 750 mg q12h. For E. coli and K. pneumoniae the PTA was <90 % even with the highest, simulated dosage of 1500 mg q6h. For S. aureus a dosage of 1500 mg q8h gave a PTA above 97 %. Conclusions. S. pneumoniae is most likely treatable with a two-daily dose of 750 mg cefuroxime. Not treatable are K. pneumoniae and E. coli . For S. aureus 1500 mg q8h constitutes an optimal dosing schedule.

9 July 2012 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
STSara Thønnings
Sara Thønnings
CØChristian Østergaard
Christian Østergaard
Optimal antibiotic treatment strategies of Haemophilus infections are still needed. Therefore, 30-day case fatality rate (CFR) of Haemophilus bacteremia and efficacy of various antibiotic treatment regimes were studied.